Mrkt BUZZ Pila Pharma: Receives go-ahead for start of obesity trials
PILA
Carlsquare Equity Research has published a comment on today’s news regarding EMA approval for the start of a new clinical trial for XEN-D0501
Read the comment here
Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity
Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11
GICS sectors. The senior equity research team has extensive experience about the stock
environment and several business sectors. The team produces company research reports
independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. Read more
Contacts
MARKUS AUGUSTSSON
Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20
NIKLAS ELMHAMMER
Senior Equity Analyst
niklas.elmhammer@carlsquare.com
+46 (0)70 898 39 59
Attachments
Mrkt BUZZ Pila Pharma: Receives go-ahead for start of obesity trials
MFN by Modular FinanceStrategy, business, and productsSwedish stocks
